Truist lowered the firm’s price target on AbCellera (ABCL) to $10 from $28 and keeps a Buy rating on the shares. The firm has updated its model after the company’s Q1 results, though it continues to be positive about AbCellera, highlighting its continued execution of their wholly owned clinical pipeline, and given the company’s hybrid business model with a focus shifting towards a clinical stage biotech, Truist is also updating its discount rate to reflect the transition, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera Biologics Receives Health Canada Approval for Trial
- AbCellera receives NOL from Health Canada for ABCL635 clinical trial application
- AbCellera Wins Patent Appeal Against Bruker
- AbCellera says Federal Circuit rejects Bruker Cellular’s invalidity challenge
- AbCellera Biologics: Promising Antibody Discovery with Strong Liquidity and Strategic Partnerships